Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lalezari

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19Bruce K Patterson, Harish Seethamraju, Kush Dhody, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Plos Pathogens|March 31, 2022
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two speciesXiao L Chang, Jason S Reed, Gabriela M Webb, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19Bruce K Patterson, Harish Seethamraju, Kush Dhody, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Plos Pathogens|March 31, 2022
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two speciesXiao L Chang, Jason S Reed, Gabriela M Webb, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Pageof 13